HER2-targeted
Photochemical activation of MH3-B1/rGel: a HER2-targeted treatment approach for ovarian cancer
... although HER2 was more pronounced in SK-BR-3 cells in agreement with a previous report ...of HER2 found in SK-BR-3 cells could, however, not explain the ~60-fold higher TI (72 hrs incubation) of MH3-B1/rGel ...
16
A novel mechanism of action of HER2 targeted immunotherapy is explained by inhibition of NRF2 function in ovarian cancer cells
... of HER2-related cancers and the emergence of novel anti-HER2 drugs for the treatment of ...of HER2 targeting and blockade by the novel combination of Trastuzumab with Pertuzumab [32, ...these ...
28
Survival, healthcare resource use and costs among stage IV ER + breast cancer patients not receiving HER2 targeted therapy: a retrospective analysis of linked SEER Medicare data
... Few population-based studies of survival among women with advanced HR + breast cancer exist. A recently pub- lished study of SEER registry data by Johnson and col- leagues estimated 5-year survival of distant breast ...
10
Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer
... of HER2 as trastuzumab, with similar affinities and the same anti-proliferative ...in HER2-overex- pressing solid tumors reported meaningful clinical activ- ity ...in HER2+ mBC patients with ...
14
Targeted Drug Delivery and Image-Guided Therapy of Heterogeneous Ovarian Cancer Using HER2-Targeted Theranostic Nanoparticles
... various targeted nanoparticle drug carriers [37, 38]. HER2 is a well-characterized biomarker for the development of targeted therapeutics, despite its heterogeneous levels of expression in human ...
18
The benefit of HER2 targeted therapies on overall survival of patients with metastatic HER2 positive breast cancer – a systematic review
... with HER2+ metastatic BC, the risk of cardiac dysfunction is justified given the improvement in OS associated with trastuzumab (Seidman et ...developed HER2-targeted therapeutic alterna- tives have ...
14
CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models
... to HER2-targeted ...membrane HER2 or cytoplasmic signaling is associated with ...of HER2 positive models. The one exception encountered was a rare HER2-positive tumor that harbored loss ...
12
A novel far-red fluorescent xenograft model of ovarian carcinoma for preclinical evaluation of HER2-targeted immunotoxins
... receptor HER2, a promising molecular target of solid ...created HER2-targeted recombinant immunotoxin based on the 4D5scFv antibody and a fragment of the Pseudomonas exotoxin ...
10
A novel mechanism of action of HER2 targeted immunotherapy is explained by inhibition of NRF2 function in ovarian cancer cells
... of HER2-related cancers and the emergence of novel anti-HER2 drugs for the treatment of ...of HER2 targeting and blockade by the novel combination of Trastuzumab with Pertuzumab [32, ...these ...
28
Injectable hydrogels for the sustained delivery of a HER2-targeted antibody for preventing local relapse of HER2+ breast cancer after breast-conserving surgery
... Finally, a HER2+ recurrent breast tumor model was established by imitative BCT on nude mice. We found that the anti-relapse efficacy was dependent on the dosage of Herceptin (Figure 10B-C). Both the Herceptin ...
19
Polyethylene glycol conjugated HER2 targeted peptides as a nuclear imaging probe for HER2 overexpressed gastric cancer detection in vivo
... with HER2 overexpression in vitro and in vivo ...for HER2-positive breast cancer therapy ...high HER2-specific affinity, which has been demonstrated to have similar activity to the intact antibody ...
18
Development of a human immuno-oncology therapeutic agent targeting HER2: targeted delivery of granzyme B
... Plasmid construction, protein expression and purification The GrB-Fc-4D5 and GrB(S195A)-Fc-4D5 constructs were generated by an overlapping polymerase chain re- action method. Briefly, cDNA encoding human GrB was fused ...
14
Mislocalization of p27 to the cytoplasm of breast cancer cells confers resistance to anti-HER2 targeted therapy
... following Her2− human breast cancer cell lines were used: HCC38, HCC1395, HCC70, MDA231, MDA468, HCC1806, HCC1143 and ...following HER2+ breast cancer cell lines were used: HCC202, HCC1569, HCC1419, BT474, ...
11
Immunological Responses against HER2-targeted Idarubicin-ZHER2 Conjugate in BALB/c Mice
... conjugate can be successfully used for specific ablation of HN5 cell line as a HER2-positive head and neck squamous cell carcinoma (HNSCC) and MCF-7 breast cancer cell line. 22 But, in vivo immunological responses ...
10
ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapy
... Tumor burden was measured as the sum of the largest diameters of the target lesions. Clinical response was evaluated every two cycles as per RECIST v1.1 [40]. Primary resistance referred to disease progression on the ...
12
Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status
... for HER2-targeted ther- apy are based on immunohistochemical detection of HER2 over-expression and demonstration of HER2 gene amplifica- tion by fluorescence in situ hybridization (FISH) in ...
8
<p>Response to Pyrotinib in a Chinese Patient with Bone-Metastatic Scrotal Paget’s Disease Harboring Triple Uncommon HER2 Mutation: A Case Report</p>
... harbor HER2 ampli fi cation or overexpression. 7 And Her2-targeted trastu- zumab monotherapy for EMPD patients has been described as clinical bene fi t with median progression-free survival (mPFS) from ...
5
Breast cancer brain metastases: the last frontier
... with HER2-positive metastatic breast cancer have experienced a dramatic improvement in overall survival with optimal the utilization of HER2 targeted therapy ...the HER2-positive breast cancer ...
10
The effects of naloxone on human breast cancer progression: in vitro and in vivo studies on MDA.MB231 cells
... For these reasons, in order to elucidate the role of naloxone in the regulation of tumor growth we performed in vitro and in vivo studies on the MDA.MB231 breast cancer cells. It is interesting to underline that ...
7
Optimizing fresh specimen staining for rapid identification of tumor biomarkers during surgery
... of targeted fluorescent probes in normal tissue despite efforts to apply blocking solution prior to staining, particularly in surrounding adipose tissue, a main component of resected breast ...the targeted ...
13